Toxicidad cardiovascular y renal de los antiinflamatorios no esteroideos
Barra lateral del artículo
Contenido principal del artículo
Resumen
.
Downloads
Detalles del artículo
Sección
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
Cómo citar
Referencias
catoggio lJ. Anti-inflamatorios no esteroideos: situación 2005. rev Hosp Ital B.Aires. 2005;25(3-4):99-106.
Grosser t, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of coX-2 inhibition: therapeutic challenges and opportunities. J clin Invest. 2006;116(1):4-15. DOI: https://doi.org/10.1172/JCI27291
Mitchell J A, lucasr, Vojnovic I, et al. Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events. FASEB J. 2006;20(14):2468-75. DOI: https://doi.org/10.1096/fj.06-6615com
Beltono, Byrne D, Kearney D, et al.cyclooxygenase-1 and -2-dependentprostacyclin formation in patients with atherosclerosis. circulation. 2000;102(8):840-5. DOI: https://doi.org/10.1161/01.CIR.102.8.840
Antman EM, Bennett JS, Daugherty A, et al. use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. circulation. 2007;115(12):1634-42. DOI: https://doi.org/10.1161/CIRCULATIONAHA.106.181424
rudic rD, Brinster D, cheng Y, et al. coX-2-derived prostacyclin modulates vascular remodeling. circ res. 2005;96(12):1240-7 DOI: https://doi.org/10.1161/01.RES.0000170888.11669.28
Perneger tV, Whelton PK, Klag MJ. risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med. 1994;331(25):1675-9. DOI: https://doi.org/10.1056/NEJM199412223312502
cheng HF, Harris rc. cyclooxygenases, the kidney, and hypertension. Hypertension. 2004;43(3):525-30. DOI: https://doi.org/10.1161/01.HYP.0000116221.27079.ea
Hao cM, Breyer MD. Hypertension and cyclooxygenase-2 inhibitors: target: the renal medulla. Hypertension. 2004;44(4):396-7. DOI: https://doi.org/10.1161/01.HYP.0000140925.73081.4c
Gurwitz JH, Avorn J, Bohn rl, et al. Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA. 1994;272(10):781-6. DOI: https://doi.org/10.1001/jama.1994.03520100043031
Qi Z, Hao cM, langenbach rI, et al. opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J clin Invest. 2002;110(1):61-9. Errata en: J clin Invest 2002;110(3):419. DOI: https://doi.org/10.1172/JCI200214752
Morgan t, Anderson A. the effect of nonsteroidal anti-inflammatory drugs on blood pressure in patients treated with different antihypertensive drugs. J clin Hypertens (Greenwich). 2003;5(1):53-7. DOI: https://doi.org/10.1111/j.1524-6175.2003.00514.x
Knights KM, Mangoni AA, Miners Jo. Non-selective nonsteroidal anti-inflammatory drugs and cardiovascular events: is aldosterone the silent partner in crime? Br J clin Pharmacol. 2006;61(6):738-40. DOI: https://doi.org/10.1111/j.1365-2125.2006.02678.x
Kearney PM, Baigent c, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332(7553):1302-8. DOI: https://doi.org/10.1136/bmj.332.7553.1302
Bombardier c, laine l, reicin A, et al. comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGor Study Group. N Engl J Med. 2000;343(21):1520-8, 2 p following 1528. DOI: https://doi.org/10.1056/NEJM200011233432103
Farkouh ME, Greenberg JD, Jeger rV, et al. cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. Ann rheum Dis. 2007;66(6):764-70. DOI: https://doi.org/10.1136/ard.2006.066001
Solomon SD, Wittes J, Finn PV, et al. cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. circulation. 2008;117(16):2104-13. DOI: https://doi.org/10.1161/CIRCULATIONAHA.108.764530
lanza Fl, chan FK, Quigley EM, et al. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104(3):728-38. DOI: https://doi.org/10.14309/00000434-200903000-00035
Silverstein FE, Faich G, Goldstein Jl, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the clASS study: A randomized controlled trial. celecoxib long-term Arthritis Safety Study. JAMA. 2000;284(10):1247-55. DOI: https://doi.org/10.1001/jama.284.10.1247
chan At, Manson JE, Albert cM, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. circulation. 2006;113(12):1578-87. DOI: https://doi.org/10.1161/CIRCULATIONAHA.105.595793
Forman JP, Stampfer MJ, curhan Gc. Non-narcotic analgesic dose and risk of incident hypertension in uS women. Hypertension. 2005;46(3):500-7. DOI: https://doi.org/10.1161/01.HYP.0000177437.07240.70
Forman J P, rimm E B, curhan Gc.Frequency of analgesic use and risk of hypertension among men. Arch Intern Med. 2007;167(4):394-9. DOI: https://doi.org/10.1001/archinte.167.4.394
Hinz B, chereminao, Brune K . Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J. 2008;22(2):383-90. DOI: https://doi.org/10.1096/fj.07-8506com
Grèen K, Drvota V, Vesterqvisto. Pronounced reduction of in vivo prostacyclin synthesis in humans by acetaminophen (paracetamol). Prostaglandins. 1989;37(3):311-5 DOI: https://doi.org/10.1016/0090-6980(89)90001-4
Zhu JH, Zhang X, Mcclung JP, et al. Zn-superoxide dismutase and Se-dependent glutathione peroxidase 1 knockouts on acetaminophen-induced cell death and related signaling in murine liver. Exp Biol Med (Maywood). 2006;231(11):1726-32. DOI: https://doi.org/10.1177/153537020623101109
Strand V. Are coX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? lancet. 2007;370(9605):2138-51. DOI: https://doi.org/10.1016/S0140-6736(07)61909-6
Bhatt Dl, Scheiman J, Abraham NS, et al. AccF/AcG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American college of cardiology Foundation task Force on clinical Expert consensus Documents. circulation. 2008;118(18):1894-909 DOI: https://doi.org/10.1161/CIRCULATIONAHA.108.191087